Temozolomide for the treatment of advanced and metastatic melanoma
Status Suspended
Decision Selected
Process STA pre-2018
Referral date 01 June 2008
Topic area
  • Cancer

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Assessment Group / Evidence Review Group: TBC
Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC


Key events during the development of the guidance:

Date Update
19 February 2010

The manufacturer of temozolomide has advised us that regulatory approval for this technology is not being sought at the present time. The Institute has therefore decided to remove this appraisal from its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns please do not hesitate to contact the Project Manager for this appraisal, Cathryn Hall (020 7045 2240 or email: cathryn.hall@nice.org.uk)

For further information on our processes and methods, please see our CHTE processes and methods manual